Here's the Deal | Karo Healthcare
It is a short, manager-produced case study of how a large private equity firm frames a deal struck during a volatile market window and the operating levers it says it will pull afterward. Useful context for wealth professionals who allocate to private equity and want to see how managers describe sourcing and value creation.
Summary
By the markets & outlook deskA KKR video episode explaining the firm's agreed acquisition of Karo Healthcare, described as one of Europe's leading consumer healthcare companies with over-the-counter brands for eczema, athlete's foot, intimate health and wellness. KKR says it agreed to acquire the company in April 2025, after a period of significant market volatility following the announcement of Liberation Day tariffs, and moved quickly to secure the opportunity. The episode covers Karo's portfolio and strengths and KKR's plan to accelerate growth through digital and e-pharmacy channels, revitalizing heritage brands and supply chain efficiency.
- KKR agreed to acquire Karo Healthcare in April 2025, following market volatility just after Liberation Day tariffs were announced.
- Karo is described as a consumer healthcare company with over-the-counter brands spanning eczema, athlete's foot, intimate health and wellness.
- KKR's value creation plan focuses on expanding digital and e-pharmacy channels, revitalizing heritage brands and improving supply chain efficiency.
- The episode is structured around Karo's portfolio and strengths, core PE investment attributes and how KKR can add value.
Chapters
From the publisher’s description| Time | Chapter | Length |
|---|---|---|
| Intro | 1 min | |
| Karo's portfolio | 1 min | |
| Karo's strengths | 1 min | |
| How KKR can add value | 2 min |
Similar items
Same topic Goldman Sachs CEO David Solomon: Have We Seen the Peak in AI? | TomorrowX Summit | iCiConnections |
AI's Role in Seeing the Full Portfolio Picture | WCWealthManagement.com |
Steady Global Economic Growth in 2027 Outlook But Risks Tilted to Downside | GSGoldman Sachs |
Steady Global Economic Growth in 2027 Outlook But Risks Tilted to Downside | EGExchanges (Goldman Sachs) |
| MMMacro Markets (Guggenheim Investments) |
Get the weekly 3 to watch
Free, in the Morning BriefEvery week the Morning Brief picks three videos and podcasts worth your time, with why each one matters.
Free. Every morning. Unsubscribe from any edition in one click.
Videos and podcasts are embedded from their publishers. Selections and summaries are editorial and are not investment advice.



